Literature DB >> 19809567

F-18 FDG PET-positive fibrous dysplasia in a patient with intestinal non-Hodgkin's lymphoma.

Mi Kim1, Hyeong Su Kim, Jung Han Kim, Joo Hyun Jang, Kook Jin Chung, Mi Kyung Shin, Hee Sung Hwang, Byung Chun Kim, So Young Jung.   

Abstract

Fibrous dysplasia (FD) is a common benign bone disorder of an unclear etiology. It is known that FD can appear without an increased FDG uptake on F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). However, there are also several reports that FD showed increased FDG uptake and this mimicked malignant bone involvement on FDG-PET. Herein we describe a case of biopsy-proven FDG-PET positive FD in a patient with intestinal non-Hodgkin's lymphoma (NHL). A 45-year-old woman was diagnosed with intestinal NHL, which was removed by right hemicolectomy. After the operation, the FDG-PET/CT scan showed hypermetabolic activity in the right transverse process of the T10 vertebra. The patient then received a total of 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy every 3 weeks. After completion of the planned chemotherapy, the 2(nd) FDG-PET/CT showed increased FDG uptake (SUVmax=6.0 g/mL) of the previous bone lesion. The MR images revealed a T1-hypointense lesion with sharp borders in the same region, and this showed homogenous contrast enhancement on the fat-suppressed T1-weighted images. After the radiologic studies were carefully reviewed, the bone lesion was assumed to be benign such as FD. We performed bone biopsy and the histological examination confirmed the diagnosis of FD. In conclusion, bone lesions with FDG uptake need to be carefully interpreted when evaluating patients with known malignancy.

Entities:  

Keywords:  FDG-PET; Fibrous dysplasia; Non-Hodgkin lymphoma

Year:  2009        PMID: 19809567      PMCID: PMC2757660          DOI: 10.4143/crt.2009.41.3.171

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  15 in total

1.  PET-positive fibrous dysplasia--a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery.

Authors:  Klaus Strobel; Beata Bode; Didier Lardinois; Ulrich Exner
Journal:  Skeletal Radiol       Date:  2006-05-20       Impact factor: 2.199

2.  Avid uptake of [18F]-FDG in fibrous dysplasia can mimic skeletal involvement in Hodgkin's disease.

Authors:  C von Falck; H Rosenthal; F Laenger; J Lotz; W H Knapp; M Galanski
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-14       Impact factor: 9.236

3.  Unexpected finding of elevated glucose uptake in fibrous dysplasia mimicking malignancy: contradicting metabolism and morphology in combined PET/CT.

Authors:  Lars Stegger; Kai Uwe Juergens; Sabine Kliesch; Dag Wormanns; Matthias Weckesser
Journal:  Eur Radiol       Date:  2006-10-26       Impact factor: 5.315

4.  FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; H Ishijima; N Oya; N Sato; T Inoue; K Endo
Journal:  Radiology       Date:  2001-06       Impact factor: 11.105

5.  Tumor metabolic rates in sarcoma using FDG PET.

Authors:  J F Eary; D A Mankoff
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

6.  Bone metastasis detected by FDG PET in a patient with breast cancer and fibrous dysplasia.

Authors:  Toshirou Shigesawa; Yoshifumi Sugawara; Isao Shinohara; Takashi Fujii; Teruhito Mochizuki; Ichiro Morishige
Journal:  Clin Nucl Med       Date:  2005-08       Impact factor: 7.794

7.  F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones.

Authors:  Olivier Berrebi; Charles Steiner; A Keller; Anne-Laure Rougemont; Osman Ratib
Journal:  Clin Nucl Med       Date:  2008-07       Impact factor: 7.794

8.  Intensity of FDG uptake is not everything: synchronous liposarcoma and fibrous dysplasia in the same patient on FDG PET-CT imaging.

Authors:  Mathieu Charest; Amit Singnurkar; Marc Hickeson; J A Novales; Vilma Derbekyan
Journal:  Clin Nucl Med       Date:  2008-07       Impact factor: 7.794

9.  18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.

Authors:  Kayako Isohashi; Mitsuaki Tatsumi; Ichiro Higuchi; Atsuo Inoue; Kazuya Nakajo; Jun Ishikawa; Eku Shimosegawa; Yuzuru Kanakura; Hironobu Nakamura; Jun Hatazawa
Journal:  Ann Nucl Med       Date:  2008-11-28       Impact factor: 2.668

10.  Increased bone mineral turnover without increased glucose utilization in sclerotic and hyperplastic change in fibrous dysplasia.

Authors:  M Toba; K Hayashida; S Imakita; K Fukuchi; N Kume; Y Shimotsu; I Cho; Y Ishida; M Takamiya; S Kumita
Journal:  Ann Nucl Med       Date:  1998-06       Impact factor: 2.668

View more
  3 in total

1.  Fibrous Dysplasia Mimicking Bone Metastasis on Both Bone Scintigraphy and (18)F-FDG PET-CT: Diagnostic Dilemma in a Patient with Breast Cancer.

Authors:  Sudhir Suman Kc; Punit Sharma; Harmandeep Singh; Chandrasekhar Bal; Rakesh Kumar
Journal:  Nucl Med Mol Imaging       Date:  2012-09-15

2.  Spinal polyostotic fibrous dysplasia in two adults: Does only biopsy unravel the mystery?

Authors:  Abhay Gundgurthi; M K Garg; Reena Bhardwaj; Sandeep Kharb; Aditi Pandit; Karninder S Brar; Ravi Kumar; A G Pandit
Journal:  Indian J Endocrinol Metab       Date:  2013-11

3.  Extensive polyostotic fibrous dysplasia evaluated for malignant transformation with 99mTc-MDP bone scan and 18F-FDG PET/CT.

Authors:  William Makis; Stephan Probst
Journal:  BJR Case Rep       Date:  2016-07-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.